When was OncoSynergy founded?

OncoSynergy was founded in 2011 and raised its 1st funding round 7 years after it was founded.

Where is OncoSynergy located?

OncoSynergy is headquartered in San Francisco, United States. It is registered at Greenwich, Connecticut.

Who is the current CEO of OncoSynergy?

Shawn Carbonell of OncoSynergy.

How many employees does OncoSynergy have?

As of Dec 31, 2021, OncoSynergy has 3 employees, reflecting a 25% year-over-year decline in headcount.

Is OncoSynergy a funded company?

OncoSynergy is a funded company, having raised a total of $26.7M across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 04, 2018.

When was the latest funding round of OncoSynergy?

OncoSynergy's latest funding was a $***** Series A round on May 13, 2022, with participation from 0 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $684M in funding in 2026 to date.

Where does OncoSynergy rank among its competitors?

OncoSynergy ranks 75th amongst 227 active competitors, of which 76 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Trogenix, which secured $95M in Oct, 2025.

Who are the top competitors of OncoSynergy?

OncoSynergy's top competitors include Harbour BioMed, Zymeworks and Xilio Therapeutics. Among them, Trogenix secured the most recent funding round in October, 2025.

OncoSynergy - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of resistance mechanism inhibitors to treat cancer. It targets multiple hallmarks of cancer progression and have demonstrated efficacy as monotherapy and in strategic combinations. The lead drug program OS2966 therapeutic antibody blocking a cell surface receptor for the treatment of glioblastoma, ovarian, pancreatic cancer, and malignant meningioma.

Website: oncosynergy.com
Social
Registered Address: Greenwich, Connecticut

Key Metrics

Founded Year

2011

Location

San Francisco, United States

Stage

Acquired

Total Funding

$26.7M in 7 rounds

Latest Funding Round

Series A, May 13, 2022, $*****

Investors

Connecticut Innovations & 5 more

Ranked

75^th among 227 active competitors

Employee Count

3 as on Dec 31, 2021

Similar Companies

Harbour BioMed & 271 more

Exit Details

Acquired by DanDrit (Apr 05, 2016)

View OncoSynergy's full profile

OncoSynergy is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ONCOSYNERGY, INC. CIN: 452520717 , United States, Active	Dec 31, 1999	-	4 (As on Dec 31, 2020)	-

OncoSynergy got acquired by DanDrit on Apr 05, 2016.

Click here to take a look at OncoSynergy's acquisition in detail

OncoSynergy has raised a total funding of $26.7M over 7 rounds. Its first funding round was on May 04, 2018. OncoSynergy has 6 institutional investors.

Here is the list of recent funding rounds of OncoSynergy:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 13, 2022	6132838	Series A	9471492	6587897	5550574	8144179
Nov 24, 2020	9565216	Conventional Debt	9212295	4421801	6012347	8825100
Sep 08, 2020	5218583	Series A	4348234	3705620	8677207	8816695

Access funding benchmarks and valuations. Sign up today!

View details of OncoSynergy's funding rounds and investors

The founders of OncoSynergy is Shawn Carbonell.

Here are the details of OncoSynergy's key team members:

Shawn Carbonell: CEO and Co-Founder of OncoSynergy.
Contact Info: 1 email address

View details of OncoSynergy's Founder profiles and Board Members

OncoSynergy's employee count trend

OncoSynergy has 3 employees as of Dec 21. The total employee count is 25.0% lower than what it was in Dec 20. Here is OncoSynergy's employee count trend over the years:

Uncover OncoSynergy's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of OncoSynergy include Harbour BioMed, Zymeworks and Xilio Therapeutics. Here is the list of Top 10 competitors of OncoSynergy, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	Hudson Bay Capital, GIC & 19 others	71/100
2nd	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 16 others	70/100
3rd	Xilio Therapeutics 2016, Waltham (United States), Public	Developer of immunotherapies for the treatment of cancer	$233M	F-Prime Capital, Rock Springs Capital & 16 others	62/100
4th	Ambrx 2003, San Diego (United States), Acquired	Developer of Antibody drug conjugates to treat cancers, metabolic disorders and cardiovascular disorders	$346M	Glynn Capital, Apricot Capital & 23 others	62/100
5th	AVEO Pharmaceuticals 2001, Cambridge (United States), Acquired	Developer of small molecules of drugs for the treatment of cancer	$146M	Bessemer Venture Partners, New Enterprise Associates ... & 14 others	61/100
6th	Trogenix 2023, Edinburgh (United Kingdom), Series A	Developer of precision cancer treatments using its proprietary gene therapy platform	$111M	IQ Capital, AIN.UA & 9 others	61/100
7th	BioAtla 2007, San Diego (United States), Public	Developer of immunotherapies for cancer using active biologics platform	$162M	Soleus Capital, HBM Healthcare Investments ... & 15 others	61/100
8th	Merus 2003, Utrecht (Netherlands), Acquired	Developer of antibody-based drugs for cancer treatment	$156M	Eurostars, Life Sciences Partners & 15 others	61/100
9th	Oncoinvent 2010, Oslo (Norway), Public	Developer of radioisotope-based anti-cancer therapeutics	$30.7M	Canica, Hadean Ventures & 8 others	61/100
10th	Canbridge Life Sciences 2012, Beijing (China), Public	Developer of therapeutics for rare diseases and cancer	$186M	SPDB International Holdings, Casdin Capital ... & 15 others	60/100
75th	OncoSynergy 2011, San Francisco (United States), Acquired	Developer of resistance mechanism inhibitors to treat cancer	$26.7M	National Cancer Institute, JLABS & 4 others	39/100